British American Tobacco: Clearing the Air - [Business Breakdowns, EP.162]
At a Glance
Evan Tindall (Co-founder and CIO of Bireme Capital) starts from thousands of years of tobacco history and analyzes BAT's business model, market evolution, and investment logic. The most significant judgment in the entire episode: BAT is transitioning from a "melting ice cube" (irreversible decline of traditional tobacco) to a structural shift driven by next-generation products. If the market realizes this, its valuation could move from 6x free cash flow toward Philip Morris's 14x, implying a doubling of the stock price.
Theme 1: Tobacco History is Regulatory History — Industry Structure Shaped by the "Government's Hand"
Evan Tindall argues that the competitive landscape and profit margin stability of the modern tobacco industry are fundamentally locked in by regulatory bans and tax policies.
Historical Context
- In 1880, the Bonsac cigarette machine increased daily output from a few hundred to 70,000 cigarettes, cutting costs by over 50%. Buck Duke used this to establish the American Tobacco Company, monopolizing the U.S. market.
- In 1911, the Supreme Court, under the Sherman Antitrust Act, broke up American Tobacco into three companies — similar to the breakup of Standard Oil, but the tobacco breakup is less discussed.
- In 1901, Duke attempted to invade the British market. Thirteen British companies jointly formed Imperial Tobacco to counterattack. A year later, the two sides reached an agreement: "each monopolizes its domestic market + jointly establishes BAT to expand overseas" — BAT thus got its name, essentially a product of the Anglo-American tobacco giants carving up the global market.
- In 1998, the Master Settlement Agreement: major manufacturers agreed to pay states approximately $200 billion (over 25 years, about $9 billion per year), directly leading to Philip Morris splitting into Altria (retaining U.S. business) and Philip Morris International.
Mechanism Breakdown
- Advertising bans (in the U.S. and most developed countries, prohibiting TV/radio/print ads) actually constitute a moat: new brands cannot build awareness, and the existing brand competitive landscape is "frozen." "If you go to a VC to pitch a new cigarette brand, you'll be laughed out of the room."
- Tax burden is extremely high: the global tobacco market is about $800 billion, of which 25% is taxes — "a quarter is taken off the top before you even start."
- High excise taxes not only compress profits but also raise the pricing threshold, further deterring new entrants.
Current Landscape
- U.S. market: Altria (Marlboro) is first, BAT (Newport/Camel/Kent, etc.) is a strong second; overseas, Philip Morris International is the largest, and its iQOS has surpassed Marlboro to become its largest brand.
- BAT's debt structure: In 2017, it fully acquired R.J. Reynolds (previously held 42%), adding approximately $50 billion in debt, which it is still repaying.
Theme 2: Next-Generation Products Are Rewriting the 'Industry Decline' Narrative
Evan Tindall notes that the low-single-digit volume decline in traditional tobacco is offset by growth in next-generation products, and total U.S. nicotine intake (measured in equivalent cigarette packs) is actually growing.
Data Chain
- BAT revenue structure: traditional tobacco ~£24 billion, next-generation products (reduced-risk categories) ~£3 billion, with the latter accounting for roughly 11-12% and growing far faster than the former.
- U.S. traditional cigarette volumes fell about 10% in 2023, after years of 2-4% annual declines; but through price increases (supported by oligopolistic pricing power), BAT's revenue was roughly flat.
- Altria data: converting various nicotine products into equivalent cigarette packs, the U.S. market has actually grown at an average annual rate of 1% over the past five years—because the decline in traditional volumes is offset by growth in pods, nicotine pouches, etc.
- Japan is the market with the highest penetration of next-generation products globally: about 30% of revenue comes from heated tobacco products, and the overall market is still growing at low single digits.
Mechanism Breakdown
- Nicotine pouches (such as Zyn, Velo) are growing at an astonishing pace: Philip Morris's Zyn guides 60% volume growth; BAT's Velo (European version) grew 35% in 2023.
- Growth drivers: pure nicotine (not tobacco-derived, no tobacco-specific nitrosamines) → can be flavored → 'a cleaner, tastier addictive product' → actual demand elasticity may be far greater than market consensus.
- However, Zyn has not yet received full FDA approval in the U.S. (it is in a gray area where sales are allowed to continue during litigation), and BAT's Velo 2.0 (European version) is not approved in the U.S.; currently only Velo 1.0 is sold. 'It is said that Canadian hockey players import Velo 2.0 from Europe because they think it is better than Zyn.'
Extrapolation and Uncertainties
- Time horizon: On a 10-year view, next-generation products could account for 50% of BAT's revenue—at which point the market will reassess its 'declining stock' label.
- Falsification signal: If Velo 2.0, after approval in the U.S., cannot break Zyn's dominant market share, BAT's competitive position in the next-generation product track will be lower than expected.
Theme 3: Financial Model – Stable Cash Flows + Extreme Discount, but Be Wary of the Menthol Ban
Evan Tindall argues that BAT's business model offers a "rare margin of safety": 6x free cash flow, a 10% dividend yield, and a solid payout base.
Profitability Data
- Gross margin: 78% in 2013 → an estimated 83% in 2024, consistently improving.
- Operating margin: roughly 40% over the long term.
- Capital expenditure is extremely low: operating cash flow of £9.2 billion in 2023, CapEx of only £0.5 billion, free cash flow conversion rate close to 100%.
- Debt: approximately £50 billion in debt when R.J. Reynolds was acquired in 2017, which has been continuously repaid, with dividends paid of £5 billion (corresponding to a dividend yield of about 10%).
Comparison with Philip Morris
- BAT currently trades at about 6x free cash flow, versus Philip Morris at about 14x.
- If BAT's valuation were to converge toward PM's, the stock price would need to double.
- The difference partly stems from PM being more advanced in the transition to next-generation products (about 30–40% of revenue) and PM trading primarily in the U.S. (less pressure from ESG selling), while BAT is listed in London, where "European investors' obsession with ESG subjects tobacco stocks to a larger discount."
Biggest Risk: Menthol Ban
- Background: The U.S. FDA (under the Biden administration) has repeatedly mentioned banning menthol cigarettes.
- Impact on BAT: roughly 40–50% of cigarette revenue in the U.S. comes from menthol (Newport is its largest brand), accounting for about 25% of total revenue.
- Scenario analysis: some consumers switch to non-menthol versions, some switch to other brands, and some quit smoking – BAT could lose 10–15% of profits (about $1 billion).
- Current assessment: Tindall believes this risk is already fully priced in (the 6x valuation already implies a pessimistic outlook), and if Trump were elected, the ban might not be pursued, but "this is indeed a real tail risk."
Capital Allocation Outlook
- Tindall does not expect large-scale M&A: "growth companies have largely been acquired (Swedish Match/Zyn being an exception), and regulatory approvals are getting harder."
- BAT has invested about £200 million in a legal cannabis company in Canada, but "it is expected to be only a rounding error in terms of profit contribution for the foreseeable future."
提及的标的
| Instrument |
Guest's View |
Key Data |
| British American Tobacco (BAT) |
Bullish (undervalued, in transition) |
6x free cash flow, 10% dividend yield, £2.4bn / £300m traditional/new category revenue |
| Altria |
Neutral (for comparison) |
#1 in US, dominated by traditional products, once invested in Juul |
| Philip Morris International |
Slightly bullish (transition leader) |
30-40% revenue from next-gen products, 14x PE, iQOS has surpassed Marlboro |
| Swedish Match (Zyn) |
Mentioned as owner of Zyn brand, acquired by PM |
Acquired at 22x EBITDA, later became a "rocket ship" |
| Juul |
Neutral (historical case) |
From "ubiquitous" to regulatory crackdown, Altria once invested |
| Imperial Brands |
Mentioned for context |
Participated in 1998 Master Settlement |
| R.J. Reynolds |
Historical acquisition target |
Fully acquired by BAT in 2017 |
| Lorillard |
Historical acquisition target |
Acquired in 2014, brought the Newport brand |
Memorable Judgments
1. "Banned advertising actually creates a moat" (Evan Tindall): Advertising bans freeze brand awareness; new brands cannot build recognition, and the competitive landscape of old-line oligopolies (BAT, Altria, PM) is nearly unassailable.
2. "Overall nicotine consumption in the US is actually growing, not declining" (Evan Tindall): Altria data shows that when all nicotine products are converted into equivalent cigarette packs, actual consumption has grown 1% annually over the past five years—because the decline in traditional volumes has been fully offset by the increase in next-generation products.
3. "Zyn's astonishing growth proves that even without advertising, a good enough product can build brand loyalty in a constrained environment" (Evan Tindall): Zyn's success demonstrates that in a severely restricted marketing environment, product strength + word-of-mouth + distribution capability can still create a dominant brand—challenging the conventional wisdom that "without advertising, you cannot build a brand."
4. "BAT's transformation from a 'melting ice cube' to a 'new growth engine' may take 10 years to reach 50% of revenue from next-generation products—but the market hasn't started pricing in this shift yet" (Evan Tindall): Current valuations fully reflect the decline of traditional tobacco but do not reflect the reshaping of the long-term growth curve by next-generation products.
5. "A menthol ban could cost BAT 10-15% of its profits—but that is already priced into the 6x valuation" (Evan Tindall): Even in the worst-case scenario, BAT's valuation discount may have already absorbed most of the risk, offering an asymmetric "limited downside + huge upside."
6. "If Velo 2.0 gains FDA approval in the US, it could become a true challenger to Zyn—Canadian hockey players are already using it as a 'smuggled good'" (Evan Tindall): BAT's Velo 2.0 product in Europe is privately considered superior to Zyn, but it has yet to receive FDA approval—this is BAT's most critical catalyst in next-generation products.
7. "10% dividend yield + 6x free cash flow—this is not a 'cigar butt,' it is a stable cash flow machine that might be in the midst of a transformation" (Evan Tindall): Compared to Buffett-style "cigar butts" (the last puff of profit), BAT's logic is: traditional businesses provide stable cash flow, next-generation businesses provide growth options, and extreme valuations provide a margin of safety.
8. "ESG selling may have actually created an opportunity—when European pension funds and large institutions firmly avoid tobacco, it gives those willing to do deep research a discounted entry point" (Evan Tindall): BAT, listed in London, bears a larger ESG discount than PM, listed in the US, but this "institutional bias" may diminish over the next 10-15 years as products become less harmful.